Benefits of SGLT2 inhibitors in arrhythmias

Jinghan Gao; Genlong Xue; Ge Zhan; Xinying Wang; Jiatian Li; Xiaolei Yang; Yunlong Xia

doi:10.3389/fcvm.2022.1011429

Benefits of SGLT2 inhibitors in arrhythmias

Front Cardiovasc Med. 2022 Oct 20:9:1011429. doi: 10.3389/fcvm.2022.1011429. eCollection 2022.

Authors

Jinghan Gao¹, Genlong Xue¹, Ge Zhan¹, Xinying Wang¹, Jiatian Li¹, Xiaolei Yang¹, Yunlong Xia¹

Affiliation

¹ Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.

Abstract

Some studies have shown that sodium-glucose cotransporter (SGLT) 2 inhibitors can definitively attenuate the occurrence of cardiovascular diseases such as heart failure (HF), dilated cardiomyopathy (DCM), and myocardial infarction. With the development of research, SGLT2 inhibitors can also reduce the risk of arrhythmias. So in this review, how SGLT2 inhibitors play a role in reducing the risk of arrhythmia from the perspective of electrical remodeling and structural remodeling are explored and then the possible mechanisms are discussed. Specifically, we focus on the role of SGLT2 inhibitors in Na⁺ and Ca^{2 +} homeostasis and the transients of Na⁺ and Ca^{2 +}, which could affect electrical remodeling and then lead to arrythmia. We also discuss the protective role of SGLT2 inhibitors in structural remodeling from the perspective of fibrosis, inflammation, oxidative stress, and apoptosis. Ultimately, it is clear that SGLT2 inhibitors have significant benefits on cardiovascular diseases such as HF, myocardial hypertrophy and myocardial infarction. It can be expected that SGLT2 inhibitors can reduce the risk of arrhythmia.

Keywords: SGLT2 inhibitors; arrhythmia; electrical remodeling; mechanisms; structural remodeling.

Publication types

Review